PubMed Health⌕ Search

PubMed · 11710220

Cyclic aromatic systems with hypervalent centers.

Abstract

Strong attractive intramolecular X<--Y(S, NR') interactions of 1,5-type occurring between terminal electron-rich main-group 15-17 centers (X = pnictogen, chalcogen, or halogen) and carbonyl, thione, or imine groups (Y = O, S, NR') incorporated into the conjugated -X-CH=CH-CH=Y fragments result in significant stabilization of cis-s-cis structure of these molecules, which may be viewed as the five-membered pseudo-heterocycles with the hypervalent arrangements across the pnictogen, chalcogen, or halogen centers. In derivatives of beta-chalcovinylaldehydes and isoelectronic chloronium cations, one of two lone electron pairs at X = S, Se, Te, Cl+ possesses pure p character and is involved in conjugation with the pi-system of the rest of the molecule, which leads to an appreciable contribution of the aromatic stabilization of the 6 pi-electron ring closed by the X<--Y bond. The aromaticity of these structures evaluated through calculation of the homodesmotic stabilization energies (HSE) increases in parallel with an increase in the strength of the intramolecular coordination bonds, i.e., in the order X = S, Se, Te and with an increase in electronegativity of a substituent attached to the chalcogen atom. Clear manifestation of the aromatic character of the cis-s-cis isomers of beta-chalcovinylaldehydes, their imines, as well as congeneric thiones and chloronium cations comes from the theoretical and experimental evidence for the pronounced equalization (as compared with the open trans-s-trans isomers) of the CC bond lengths. The cooperative effects of the hypervalent bonding and aromaticity are most distinct in the bicyclic structures of 1,6,6a lambda 4-trichalcapentalenes, their 1,6-dioxa(aza) analogues, and 1,6-dioxa-3a-aza-6a lambda 4-pnictapentalenes, in which two conjugated -X-CH=CH-CH=Y fragments are fused together via the symmetric -Y-X-Y- triad. The assessments based on the HSE values indicate that the aromaticity of these 10 pi-electron compounds is estimated as about 30-50% of the aromatic character of the most aromatic bicyclic structure of naphthalene. As shown by extensive ab initio calculations, substantial hypervalent bonding effects also operate in the case of beta-pnictovinylaldehydes formed by second and lower row pnictogen atoms (X = P, As, Sb, Bi), providing for the enhanced stability of their cis-s-cis configuration with respect to the free-of-strain trans-s-trans structures. The bicyclic 1,6,6a lambda 5-dioxapnictapentalene structure is also the most energy favorable form of these compounds. However, by contrast with the chalcogen and halonium analogues, the pseudo-cyclic structure of beta-pnictovinylaldehydes and the bicyclic structure of 1,6,6a lambda 5-dioxapnictapentalenes are maintained through primarily the occurrence of the hypervalent bonding across the pnictogen centers, whereas pi-delocalization is not (or weakly) operative in these compounds. A possible explanation for this finding is the low p character of the single lone electron pair at the pnictogen and orientation of the axis of its orbital, which is unfavorable for the optimal overlap with the pi-system of the rest of a molecule. As first proposed by Arduengo and Dixon, configurational isomerizations at the second and lower row tricoordinate pnictogen centers may proceed through the T-shaped hypervalent structures. Such a structure is strongly stabilized in the aromatic 1,6-dioxa-3a-aza-6a lambda 4-pnictapentalenes. It was found by calculations that the aromatic stabilization of the T-shaped hypervalent arrangement at the tricoordinate pnictogen center in 2H-1,3,2-dioxaphosphole and arsole arising due to withdrawal of two electrons from the pi-system of the ring onto the hypervalent electron-excessive center facilitates the rearrangement and directs it along the reaction path with the aromatic transition-state structure. Investigation of the influence of cooperative effects of hypervalent bonding and aromaticity on stability and mechanisms of reactions of main-group 14-17 compounds not considered in this review is the subject of our continuing research.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

V I Minkin, R M Minyaev. 2001. Cyclic aromatic systems with hypervalent centers.. https://doi.org/10.1021/cr990358h

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗